Gilead Sciences, Inc. today announced 48-week results from a Phase 2 study evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection.
http://it.tmcnet.com/news/2013/09/12/7407356.htm
http://it.tmcnet.com/news/2013/09/12/7407356.htm
No comments:
Post a Comment